HemaCare, A Charles River Company: Cell Therapy Solutions



February 20, 2020

  • Share
  • HemaCare is a global leader in providing human-derived biological products and apheresis collection services, directly enabling customers to advance autologous and allogeneic cell therapies. With over 40 years of experience, HemaCare has performed over 300,000 apheresis collections, developed the largest registry of healthy, repeat donors, and adopted the most stringent quality standards in the industry to provide customers with the highest quality starting material and primary cells available today.

    HemaCare is also the first commercial provider of GMP-compliant human primary cells isolated from leukopaks and bone marrow collected onsite. Our GMP-compliant materials are collected following consistent collection procedures and processes, ensuring the highest quality GMP starting material to support global cell therapy from product and process development to commercialization.

    HemaCare’s GMP capabilities include:
    • Leukopak and Bone Marrow Aspirate collections
    • Cell processing and isolation within a clean room environment (T cells, NK cells, etc.)
    • Cryopreservation and storage
    • Customization of collection and services to meet protocol specifications
    • Technology transfer of client-specific protocols for GMP

    To learn more about HemaCare’s role in commercializing patient cell therapies and how we may be able to assist you on your next project, please contact us at https://www.hemacare.com/contact/.

    Connect with HemaCare Online: Visit HemaCare’s Website: https://www.hemacare.com/
    Follow HemaCare on LinkedIn: https://bit.ly/314zF81
    Follow HemaCare on Twitter: https://bit.ly/2Y9qAxs
    Follow HemaCare on Facebook: https://bit.ly/32TIjrF

    Cancer ResearchDrug DiscoveryStem Cells

    Keep up to date with all your favourite videos and channels.

    Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.